KR0164215B1 - 사람 유두종바이러스 제16형 e7 단백질상의 면역원성 서열을 갖는 폴리펩타이드 - Google Patents
사람 유두종바이러스 제16형 e7 단백질상의 면역원성 서열을 갖는 폴리펩타이드 Download PDFInfo
- Publication number
- KR0164215B1 KR0164215B1 KR1019900003101A KR900003101A KR0164215B1 KR 0164215 B1 KR0164215 B1 KR 0164215B1 KR 1019900003101 A KR1019900003101 A KR 1019900003101A KR 900003101 A KR900003101 A KR 900003101A KR 0164215 B1 KR0164215 B1 KR 0164215B1
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- hpv
- polyreptide
- immanogenic
- type16
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 8
- 102000004169 proteins and genes Human genes 0.000 title claims description 8
- 241000341655 Human papillomavirus type 16 Species 0.000 title claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000702374 Enterobacteria phage fd Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
내용 없음.
Description
본 발명은 사람 유두종바이러스 제16형(human paillomavirus type 16: HPV 16) E7 단백질상의 두 개의 면역원성 영역에 관한것으로서, 하나의 면역반응성 영역은 HPV 16 게놈의 뉴클레오타이드 위치 595 3'에 위치하며 다른 하나는 HPV 16게놈의 뉴클레오타이드 위치 667의 3'에 위치한다.
유두종바이러스 는 배양할 수 없다. 따라서, HPV DNA를 진단보조제로서 사용하거나, HPV DNA의 발현 생성물을 수득한후 이를 항원으로서 사용하여 항체를 분리한 후 상응하는 진단보조제를 제조하기 위해서는 유전공학방법을 이용해야 한다.
뒤르스트(Durst) 등[참조: Proc. Natl. Acad. Sci. USA 80(1983) 3813-3815]은 HPV 16이라 불리우는 사람 유두종바이러스 (HPV)의 신규한 유형에 대해 기술하고 있다. 상기 바이러스는 DNA 서열 및 게놈 체계가 문헌[참조: Seedorf et al. Virology 145(1985) 181-185]에서 재현되었다.
스모트킨(Smotkin) 및 웨트스타인(Wettstein)[참조: Proc. Natl. Acad. Sci. USA 83. 4680-4684(1986)]은 CaSki 세포주 및 HPV 16 DNA를 주로 플라스미드로서 함유하는 기타 경부종양에서 가장 빈번하게 생성되는 HPV 전사체로서 E7 전사체를 동정했다. 또한, 문헌[참조: Seedorf et al., EMBO J. 6, 139-144(1987)]에서는 HPV 16을 통합된 형태로 또는 폴리스미드로서 함유하는 상기 세포주내에서 가장 빈번하게 생성되는 바이러스성 HPV 16 단백질이 E7 단백질임을 밝히고 있다.
또한, E7 단백질은 형질전환된 표현형을 유지하는데 관여하는 것으로 여겨진다. 또한, E7 단백질에 대한 항체는 경부 종양 환자에 있어 일반적이다. 따라서, HPV 16 E7 단백질 또는 이에 대한 항체를 검측하는 것이 진단에서 중요하다.
클로닝된 HPV 16 DNA의 숏건(shotgun) 발현 뱅크를 래비트의 HPV 16 E7에 대한 폴리클로날 항혈청으로 분석한 결과, E7 단백질내에서 2개의 면역반응성 영역이 발견되었다. 제1 영역은 E7의 N-말단부에 존재하며, 다음과 같은 상이한 크기의 4개의 파아지 클론으로 표현된다:
이때, 클론의 5' 말단은 HPV 16 게놈상의 뉴클레오타이드 위치 595에 상응한다.
상응하는 5부류의 아미노산 서열은 다음과 같다:
HPV 16 E7의 제2 면역반응성 영역은 HPV 16 게놈상의 뉴클레오타이드 위치 667에 위치한다.
상응하게, 다음과 같은 17개의 아미노산을 포함한다.
따라서, 본 발명은 상기 언급된 2개의 면역반응성 영역, 및 진단과 치료를 위한 이의 용도 및 약제 또는 백신으로서의 이의 용도에 관한 것이다.
더우기, 본 발명은 실시예 및 특허청구범위내에 포함된다.
[실시예]
1. HPV 16 게놈의 숏건 발현 뱅크의 제조
세균 플라스미드 벡터 sp65내에 클로닝된 HPV 16 DNA를 초음파 전단에 이은 DNase I 처리에 의해 약 100bp(염기-쌍)의 평균 단편 크기로 전환시킨다.
상기 단편의 말단을 T4 DNA 폴리머라제 및 이.콜라이 DNA 리가아제를 사용하여 채운다. 파아지 발현 벡터 fd-tet-J6을 PvuII로 절단하고, 단편을 평활-결합시킨다. fd-tet-J6은 박테리오파아지 fd로부터 유도되며, 문헌[참조: G.P. Smith, Science 228, 1315-1317 (1985)]에 기술되어 있다.
2. 면역원성 반응의 검측
재조합 파아지를 이.콜라이 K91상에 플레이팅한후, 니트로셀룰로오즈 필터상의 페플리카를 특정 혈청을 사용하여 면역반응성 파아지에 대해 조사한다. 200개의 재조합체가 항혈청과 반응하며; 이들중 30개를 DNA 서열 분석으로 다시 조사한다.
하기의 결과가 수득된다:
1. 모든 재조합체는 E7-특이적인 서열을 포함한다.
2. 2개의 면역원성 영역이 E7 단백질내에서 발견되었다. 제1 영역은 25개의 중첩된 클론에 의해 동정되었다. 이들 25개의 클론은 다음과 같이 4개의 부류로 나눌 수 있다:
여기서, 클론의 5' 말단은 HPV 16 게놈상의 뉴클레오타이드 위치 595에 상응한다.
상응하는 4 부류의 아미노산 서열은 다음과 같다:
따라서 이들 영역의 최소 크기는 8개의 아미노산이다. 모노클로날 항체는 단지 그룹(I) 및 (II)와 반응하지만, 폴리클로날 항혈청은 상기 4그룹 모두와 반응하므로, 그룹(I) 또는 (II)의 항원상에는 2개 이상의 상이한 에피토프가 존재한다.
그룹(II)의 아미노산 서열에 상응하는 합성 올리고펩타이드(met-leu-asp-leu-gln-glu-thr-thr-asp-leu-tyr)를 ELISA에 사용하였으며, 상기 언급된 HPV 16 E7에 대한 폴리클로날 래비트 혈청과 독특한 반응을 보였다.
17개의 아미노산을 갖는 제2 면역반응성 영역이 5개의 클론에서 발견되었으며, HPV 16 게놈상의 뉴클레오타이드 위치 667에 위치한다:
17개의 상응하는 아미노산 서열은 다음과 같다:
Claims (2)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP3907721.7 | 1989-03-10 | ||
DE3907721A DE3907721A1 (de) | 1989-03-10 | 1989-03-10 | Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900013979A KR900013979A (ko) | 1990-10-22 |
KR0164215B1 true KR0164215B1 (ko) | 1999-01-15 |
Family
ID=6375965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900003101A KR0164215B1 (ko) | 1989-03-10 | 1990-03-09 | 사람 유두종바이러스 제16형 e7 단백질상의 면역원성 서열을 갖는 폴리펩타이드 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5547846A (ko) |
EP (1) | EP0386734B1 (ko) |
JP (1) | JP3056502B2 (ko) |
KR (1) | KR0164215B1 (ko) |
AT (1) | ATE128144T1 (ko) |
AU (1) | AU624485B2 (ko) |
CA (1) | CA2011878C (ko) |
DE (2) | DE3907721A1 (ko) |
DK (1) | DK0386734T3 (ko) |
ES (1) | ES2078255T3 (ko) |
IE (1) | IE67798B1 (ko) |
PT (1) | PT93393B (ko) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2038581A1 (en) * | 1990-03-20 | 1991-09-21 | Martin Muller | Seroreactive epitopes of human papillomavirus (hpv) 16 proteins |
SE9001705D0 (sv) * | 1990-05-11 | 1990-05-11 | Medscand Ab | Saett foer diagnostik av virusbaerande tumoerer genom immunoassay |
US5932412A (en) * | 1990-05-11 | 1999-08-03 | Euro-Diagnostica Ab | Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes |
US6183745B1 (en) | 1990-12-12 | 2001-02-06 | The University Of Queensland | Subunit papilloma virus vaccine and peptides for use therein |
ES2193133T3 (es) * | 1991-07-13 | 2003-11-01 | Dade Behring Marburg Gmbh | Uso de peptidos derivados de los genes e6 y e7 de hpv-16 para fines. |
IL105554A (en) * | 1992-05-05 | 1999-08-17 | Univ Leiden | Peptides of human papillomavirus for use in preparations elicit a human T cell response |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
DE19737409A1 (de) * | 1997-08-27 | 1999-03-04 | Medigene Ag | Diagnosekit für Hauttest und Verfahren zur Durchführung desselben |
US6013258A (en) * | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
DE19819476C1 (de) * | 1998-04-30 | 2000-01-05 | Deutsches Krebsforsch | Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins |
FR2781158B1 (fr) * | 1998-07-15 | 2002-12-13 | Vacs Internat | Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications |
DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
US6200746B1 (en) | 1999-08-25 | 2001-03-13 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
US6641994B2 (en) | 1999-08-25 | 2003-11-04 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
US8128922B2 (en) * | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
GB0018050D0 (en) * | 2000-07-21 | 2000-09-13 | Norchip As | Detection of human papillomavirus mRNA |
US7318928B2 (en) * | 2000-08-01 | 2008-01-15 | The Johns Hopkins University | Molecular vaccine linking intercellular spreading protein to an antigen |
AU2001278117A1 (en) * | 2000-08-03 | 2002-02-18 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
CA2441947C (en) | 2001-03-23 | 2014-05-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Human papilloma virus immunoreactive peptides |
GB0120938D0 (en) * | 2001-08-29 | 2001-10-17 | Norchip As | Detection of human papillomavirus E7 mRNA |
AU2003284239B2 (en) * | 2002-10-21 | 2008-08-21 | Eisai Inc. | Compositions and methods for treating human papillomavirus-mediated disease |
WO2004098526A2 (en) * | 2003-05-05 | 2004-11-18 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
WO2006073970A2 (en) * | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
CA2595726A1 (en) * | 2005-01-26 | 2006-08-03 | The Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
WO2008024844A2 (en) * | 2006-08-22 | 2008-02-28 | The Johns Hopkins University | Anticancer combination therapies |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20080260765A1 (en) * | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
CU23674A1 (es) | 2007-07-31 | 2011-05-27 | Ct Ingenieria Genetica Biotech | Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica |
US20090285861A1 (en) * | 2008-04-17 | 2009-11-19 | Tzyy-Choou Wu | Tumor cell-based cancer immunotherapeutic compositions and methods |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4777239A (en) * | 1986-07-10 | 1988-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic peptides of human papilloma virus |
DE3722967A1 (de) * | 1987-07-11 | 1989-01-19 | Behringwerke Ag | Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung |
FR2641081A1 (ko) * | 1988-12-23 | 1990-06-29 | Medgenix Group | |
JP2791685B2 (ja) * | 1989-06-08 | 1998-08-27 | 寳酒造株式会社 | パピローマウイルスの検出方法 |
CA2038581A1 (en) * | 1990-03-20 | 1991-09-21 | Martin Muller | Seroreactive epitopes of human papillomavirus (hpv) 16 proteins |
-
1989
- 1989-03-10 DE DE3907721A patent/DE3907721A1/de not_active Withdrawn
-
1990
- 1990-03-07 AT AT90104353T patent/ATE128144T1/de not_active IP Right Cessation
- 1990-03-07 EP EP90104353A patent/EP0386734B1/de not_active Expired - Lifetime
- 1990-03-07 ES ES90104353T patent/ES2078255T3/es not_active Expired - Lifetime
- 1990-03-07 DE DE59009669T patent/DE59009669D1/de not_active Expired - Fee Related
- 1990-03-07 DK DK90104353.9T patent/DK0386734T3/da active
- 1990-03-08 AU AU51104/90A patent/AU624485B2/en not_active Ceased
- 1990-03-09 KR KR1019900003101A patent/KR0164215B1/ko not_active IP Right Cessation
- 1990-03-09 CA CA002011878A patent/CA2011878C/en not_active Expired - Fee Related
- 1990-03-09 JP JP2059801A patent/JP3056502B2/ja not_active Expired - Fee Related
- 1990-03-09 IE IE85490A patent/IE67798B1/en not_active IP Right Cessation
- 1990-03-09 PT PT93393A patent/PT93393B/pt not_active IP Right Cessation
-
1994
- 1994-08-16 US US08/292,169 patent/US5547846A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0386734A3 (de) | 1992-03-04 |
EP0386734B1 (de) | 1995-09-20 |
DE3907721A1 (de) | 1990-09-20 |
PT93393A (pt) | 1990-11-07 |
DK0386734T3 (da) | 1996-02-05 |
IE900854L (en) | 1990-09-10 |
EP0386734A2 (de) | 1990-09-12 |
JPH02289600A (ja) | 1990-11-29 |
CA2011878A1 (en) | 1990-09-10 |
DE59009669D1 (de) | 1995-10-26 |
PT93393B (pt) | 1997-01-31 |
IE67798B1 (en) | 1996-05-01 |
AU5110490A (en) | 1990-09-13 |
AU624485B2 (en) | 1992-06-11 |
JP3056502B2 (ja) | 2000-06-26 |
CA2011878C (en) | 2000-05-02 |
ES2078255T3 (es) | 1995-12-16 |
US5547846A (en) | 1996-08-20 |
KR900013979A (ko) | 1990-10-22 |
ATE128144T1 (de) | 1995-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0164215B1 (ko) | 사람 유두종바이러스 제16형 e7 단백질상의 면역원성 서열을 갖는 폴리펩타이드 | |
Cole et al. | Genome organization and nucleotide sequence of human papillomavirus type 33, which is associated with cervical cancer | |
KR930007580B1 (ko) | 유두종 비루스 게놈으로부터 유도된 결정 dna 서열, 그의 시험관내 진단 목적용 용도 및 항원 조성물의 제조 방법 | |
JP3366350B2 (ja) | Hpv‐16 e6およびe7‐遺伝子由来ペプチドの、診断のための使用 | |
JP3859696B2 (ja) | 乳頭腫ウイルスhpv39のゲノムから誘導されるdna配列、in vitro診断及び免疫原組成物の生成への前記配列の応用 | |
Lin et al. | Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product | |
JPH11504801A (ja) | パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 | |
US6322794B1 (en) | Seroreactive epitopes on proteins of human papillomavirus (HPV) 18 | |
JP3207389B2 (ja) | 乳頭腫ウィルス及びその診断方法 | |
Bleul et al. | Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients | |
US5753233A (en) | Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18 | |
AU753391B2 (en) | Protein delivery system using human papillomavirus virus-like particles | |
US6395512B1 (en) | DNA coding for a peptide of a papilloma virus main capside protein and use thereof | |
JP3140773B2 (ja) | ウイルスの検出に関する改良 | |
US6322795B1 (en) | Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses | |
Davies et al. | Definition of murine T helper cell determinants in the major capsid protein of human papillomavirus type 16 | |
Kulski et al. | Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies | |
US6610303B1 (en) | Papilloma viruses, products for the detection thereof as well as for treating diseases caused by them | |
JP2001505767A (ja) | パピローマウイルス、該ウイルスの検出用試薬および該ウイルスにより引き起こされる疾患の治療用試薬 | |
JP2001514895A (ja) | パピローマウイルス、該ウイルスの検出用試薬、および該ウイルスにより引き起こされる疾患の治療用試薬 | |
JP2002535965A (ja) | ヒトパピローマウイルス・ウイルス様粒子を使用した中和アッセイ | |
Icenogle | Analysis of the Sequences of the L1 and L2 Capsid Proteins of Papillomaviruses | |
AU773822B2 (en) | Cytotoxic T-cell epitopes of the papillomavirus L1-protein and use thereof in diagnostics and therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20050905 Year of fee payment: 8 |
|
LAPS | Lapse due to unpaid annual fee |